-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 17th, the application for the listing of Nwolly monoanti-injection fluids from Widi Pharmaceuticals is to be included in the priority review for microsatellite-highly unstable (MSI-H) advanced colorectal cancer (MSI-H) advanced cancer that has previously been treated with fluorouracils, oxalipari and Iliticone, and for DNA mismatch repair deficiencies (dR) that have failed at least the first-line standard treatment in the past.
Nvolly monoantigen (KN035) is a recombinant humanized PD-L1 monomedia antibody Fc fusion protein, developed by Corning Jerry and developed in 2016 in cooperation with Widi Pharmaceuticals, and is expected to become the world's first PD1/PD-L1 antibody to be marketed by subdermal injection.
KN035 has significant differentiation advantages compared with similar drugs on the market in terms of safety, convenience, compliance, etc., and can improve the quality of life of patients.
March 30, CorningEry entered into a cooperation agreement with Synth Pharmaceuticals and ThinkDi Pharmaceuticals to reach a strategic cooperation on the commercialization of KN035 oncology in Chinese mainland.
agreement provides that CorningEry is the sole manufacturer of KN035, responsible for the production and supply of KN03Chinese mainland5;
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.
